Government financing of vaccines and vitamin A supplementation in several African countries remains unsustainable, influenced by political economy variables, donor priorities, and systemic barriers, with explicit commitment to VAS financing notably absent. The...
The meta-regression analysis provides crucial, country-specific cost-effectiveness insights for HIV/AIDS, malaria, syphilis, and tuberculosis interventions, aiding national decision-makers in optimising health financing and resource allocation. Published in The Lancet...
Shared savings show the most promise among financial incentives for promoting cost-effective integrated care, but implementation success varies by context. The article "Financial Incentives for Integrated Care: A Scoping Review and Lessons for Evidence-Based Design,"...
Adult immunisation programmes provide substantial health and economic benefits, returning up to 19 times their cost. Governments should prioritise funding and research to maximise these benefits and support healthier societies. This study highlights the critical role...
During COVID-19, Africa's autonomous vaccine financing reduced costs and reliance on aid, highlighting a model for future health system improvements and self-reliance. Long before the COVID-19 pandemic, Africa faced the challenge of creating a sustainable model for...
The International Longevity Centre's project compiles evidence on vaccine cost-effectiveness to advocate for prioritising vaccination in global health and finance decision-making. This global project, led by the International Longevity Centre, brings together the...
While rare (orphan) diseases are a significant financial burden for health systems and access to these expensive treatments is limited, Russia has established a foundation, “Circle of Kindness”, funded by 2% of the individual income tax generated by the high-income...
